TY - CHAP M1 - Book, Section TI - Multimodality Therapy for Esophageal Cancer: Western Experience Including Definitive Chemoradiation A1 - Sepesi, Boris A1 - Hofstetter, Wayne L. A1 - Swisher, Stephen A2 - Morita, Shane Y. A2 - Balch, Charles M. A2 - Klimberg, V. Suzanne A2 - Pawlik, Timothy M. A2 - Posner, Mitchell C. A2 - Tanabe, Kenneth K. Y1 - 2018 N1 - T2 - Textbook of Complex General Surgical Oncology AB - The incidence of esophageal carcinoma in the Western world has increased more than 600% since the 1970s, mainly due to the rising incidence of adenocarcinoma.1 Therapeutic improvements in both early and locally advanced esophageal adenocarcinoma have been in part based on an understanding that gastroesophageal reflux (GER) is a precursor to esophageal cancer leading to a sequence of epithelial changes from metaplasia to progressive dysplasia, ultimately culminating in adenocarcinoma. This understanding coupled with technological advancements in endoscopic and radiographic imaging, have enhanced the surveillance and staging accuracy of esophageal cancer allowing us to both identify patients at an early stage more often, and to select patients with potentially curable disease more reliably. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/07 UR - hemonc.mhmedical.com/content.aspx?aid=1145761294 ER -